Second Pivotal Phase III Study Of Gilead’s Darusentan For Resistant Hypertension Misses Primary Endpoints

Gilead Sciences, Inc. (Nasdaq:GILD) announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo…

Original post:
Second Pivotal Phase III Study Of Gilead’s Darusentan For Resistant Hypertension Misses Primary Endpoints

Related posts:

1. BioAlliance Pharma: Breakthrough Positive Phase III Results With Acyclovir Lauriad(R) Primary And Secondary Endpoints Met – Final Results BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces final positive results of its pivotal phase III clinical study in...
2. Investigational Dual Orexin Receptor Antagonist Almorexant Meets Primary Endpoint In Two-week Phase III Study Of Primary Insomnia Actelion Ltd (SIX: ATLN) announced today that the first phase III study with almorexant (RESTORA 1) has met its primary endpoint, superiority of the dual orexin receptor antagonist almorexant compared...
3. Degarelix (FIRMAGON(R)) Vs Leuprolide (Lupron Depot(R)) In Patients With Advanced Prostate Cancer: Further Analysis From A Phase III Pivotal Trial Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III...
4. Ipsen’s Partner Roche Announces That Taspoglutide Meets Its Primary Endpoints In Head-to-Head Study With Sitagliptin (Januvia(R)) And Versus Placebo Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III...
5. Trade Alert Issued For Novelos Therapeutics, Inc. (NVLT.OB) As Pivotal Phase III Drug Trial Patients Are Living Longer Than Expected BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a trade alert for Novelos...
6. Celsion Announces Treatment Of First Patient In China In Global Phase III ThermoDox(R) Trial For Primary Liver Cancer Celsion Corporation, a leading oncology drug development company, announced today that the first patient in China has been enrolled and treated as part of Celsion's global Phase III ThermoDox HEAT...
7. Algeta Announces First US Patient Randomized In ALSYMPCA Phase III Study At Tulane Cancer Center, New Orleans Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase...
8. Novelos Therapeutics’ (NVLT.OB) CEO Is Eyeing "Revolutionary" Phase III Study Results BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive interview with the...
9. Merck KGaA Starts Stimuvax Phase III Study INSPIRE In Asian Patients With Advanced NSCLC Merck KGaA announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer...
10. Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance For Proposed INTERCEPT Blood System Phase III Trial Design Cerus Corporation (NASDAQ:CERS) announced that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III...
11. Pacira Announces Results Of Another Positive Phase III Trial In Post Operative Pain Pacira Pharmaceuticals, Inc., announced that its second Phase III placebo controlled study of EXPAREL(TM) (DepoBupivacaine) met its primary endpoint... ...
12. Roche, Genentech And Biogen Idec Announce Positive Results From First Phase III Trial Of Ocrelizumab In Rheumatoid Arthritis Roche (SIX: RO, ROG; OTCQX: RHHBY), Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) announced a Phase III study (STAGE) of the investigational...
13. Santarus Announces Completion Of Enrollment In European Phase III Clinical Trial For Budesonide MMX Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that its collaboration partner, Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA (SIX: COPN), has completed enrollment of 514...
14. Primary Endpoint Reached In Active Biotech’s TASQ Phase II Clinical Trial In Prostate Cancer Patients A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX...
15. Genentech And Biogen Idec Announce Positive Results From First Phase III Trial Of Ocrelizumab In Rheumatoid Arthritis Genentech, Inc. a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today a Phase III study (STAGE) of the investigational...

« Understanding Periodontal Gum Disease And Its Eventual Outcomes Stay Safe and Legal With the Perfect Breathalyzer »